Executives at AstraZeneca, the company that makes Crestor, say they have "no plans" to cut prices on the cholesterol-lowering drug in the face of increased competition from new generic Zocor (simvastatin). One executive referred to recent clinical trials that showed Crestor lowered LDL ("bad") cholesterol by 50 percent and reduced cholesterol build-up on artery walls as evidence that Crestor could compete with generics with current market strategies and prices.
Read moreThe JUPITER study has been the subject of countless headlines reporting the unprecedented reduction in heart attacks with the cholesterol... Read more »
A recent study has shown that a combination of Crestor and Zetia (ezetimibe) helps high-risk patients lower their cholesterol levels better than... Read more »
According to a new study, the cholesterol-lowering drug Crestor cuts the risk of stroke nearly in half in seemingly healthy people. In a trial that... Read more »
The U.S. Food and Drug Administration has approved AstraZeneca's cholesterol-lowering drug Crestor (rosuvastatin) for older adults who have healthy... Read more »
The U.S. Food and Drug Administration (FDA) has approved the cholesterol-lowering drug Crestor for kids with a genetic condition that causes high... Read more »
A panel that advises the U.S. Food and Drug Administration (FDA) has recommended that the cholesterol-lowering drug Crestor be prescribed to patients... Read more »